Simpler Grants.gov #PAR-25-106

NCI Solicitation for Innovative Cancer Nanotechnology Research Proposals

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking research proposals for innovative cancer nanotechnology projects. - Government Buyer: - National Institutes of Health (NIH), National Cancer Institute (NCI) - Scope of Solicitation: - Research projects focused on mechanistic studies of nanomaterials and nanodevices in cancer biology and oncology - Emphasis on: - Delivery of nanoparticles or nanodevices to cancer targets in vivo - Characterization of detection and diagnostic devices in vitro - Projects must generate fundamental knowledge to support future nanotechnology-based cancer interventions - Clinical translation is specifically excluded from the scope - Products/Services Requested: - No specific products, part numbers, or OEMs are identified; this is a grant opportunity for research proposals - Eligibility: - Open to government entities, businesses, educational institutions, nonprofits, and other organizations - Funding: - Minimum award amount is $475,000 - Notable Requirements: - Projects must address major barriers in cancer biology or oncology using nanotechnology - Research must be transformative and mechanistic in nature - Clinical trials or direct clinical translation are not allowed - Assistance Listings: - 93.394 (Cancer Detection and Diagnosis Research) - 93.395 (Cancer Treatment Research) - Place of Performance: - National Institutes of Health (NIH)

Description

The National Cancer Institute (NCI) invites applications for transformative research in cancer biology and oncology using nanotechnology. Projects should focus on overcoming major barriers in cancer biology through mechanistic studies of nanomaterial and nanodevice interactions with biological systems. Research should involve delivery of nanoparticles or nanodevices to cancer targets in vivo or characterization of detection and diagnostic devices in vitro. The goal is to generate fundamental knowledge to support future nanotechnology-based cancer interventions, excluding clinical translation.

View original listing